ArticleDrug delivery2019
Inhibition of microRNA-183 expression resists human umbilical vascular endothelial cells injury by upregulating expression of IRS1.
Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Fatty Acid Transporter CD36 Promotes Ox-LDL-Induced Senescence of Vascular Endothelial Cells in Preeclampsia.Journal of inflammation research · 2025Article
- Circulating miR-183-5p levels are positively associated with the presence and severity of coronary artery disease.Frontiers in cardiovascular medicine · 2023Article
- Attenuated macrophage activation mediated by microRNA-183 knockdown through targeting NR4A2.Experimental and therapeutic medicine · 2021Article
- MicroRNA-183 in Cancer Progression.Journal of Cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study aims to investigate the effect of microRNA-183 (miR-183) on human umbilical vascular endothelial cells (HUVECs) injury by targeting IRS1. HUVECs injury was induced by oxidized low-density lipoprotein (ox-LDL). HUVECs were grouped so as to explore the role of ox-LDL and miR-183 in HUVECs injury, with the expression of miR-183 and IRS1 detected. Additionally, the related factors of oxidative stress and inflammation, as well as angiogenesis ability, proliferation, cell cycle, apoptosis, invasion, and migration abilities were also measured. Ox-LDL treatment could decrease the activity of HUVECs, increase the level of oxidative stress and inflammation, and induce the HUVECs injury. miR-183 could inhibit the expression of IRS1. The inhibition of miR-183 expression in ox-LDL-induced HUVECs injury could enhance cell activity, inhibit inflammatory level, and thus resist cell injury. Low expression of IRS1 could reverse the inhibition of miR-183 on HUVECs injury. This study highlights that inhibition of miR-183 expression may resist HUVECs injury by upregulating expression of IRS1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.